5MO4

ABL1 kinase (T334I_D382N) in complex with asciminib and nilotinib

Summary for 5MO4

Entry DOI	10.2210/pdb5mo4/pdb
Descriptor	Tyrosine-protein kinase ABL1, Nilotinib, asciminib, ... (4 entities in total)
Functional Keywords	kinase, drug, inhibitor, transferase
Biological source	Homo sapiens (Human)
Cellular location	Cytoplasm, cytoskeleton. Isoform IB: Nucleus membrane; Lipid-anchor: P00519
Total number of polymer chains	1
Total formula weight	57162.53
Authors	Cowan-Jacob, S.W. (deposition date: 2016-12-13, release date: 2017-04-05, Last modification date: 2017-04-12)
Primary citation	Wylie, A.A.,Schoepfer, J.,Jahnke, W.,Cowan-Jacob, S.W.,Loo, A.,Furet, P.,Marzinzik, A.L.,Pelle, X.,Donovan, J.,Zhu, W.,Buonamici, S.,Hassan, A.Q.,Lombardo, F.,Iyer, V.,Palmer, M.,Berellini, G.,Dodd, S.,Thohan, S.,Bitter, H.,Branford, S.,Ross, D.M.,Hughes, T.P.,Petruzzelli, L.,Vanasse, K.G.,Warmuth, M.,Hofmann, F.,Keen, N.J.,Sellers, W.R. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature, 543:733-737, 2017 Cited by PubMed: 28329763 DOI: 10.1038/nature21702 PDB entries with the same primary citation
Experimental method	X-RAY DIFFRACTION (2.17 Å)

Structure validation